35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin
35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Skin Inflammation
Nakhia Impex LLC
20 participants
Apr 15, 2024
INTERVENTIONAL
Conditions
Summary
To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.
Eligibility
Inclusion Criteria3
- Skin problems include but are not limited to dry skin, dark skin, and coarse pores.
- Chronic skin inflammation, pigmentation, erythema, etc.
- Cooperate with the experimental requirements and be able to complete the score independently。
Exclusion Criteria4
- Pregnant or lactating women.
- Suffering from psychological or mental illness.
- Life is not regular, overeating.
- Hypersensitive to hyaluronic acid, and has a scar constitution.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06387212